VERU INC. - COMMON STOCK

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

18 июн 2024 15:05:00 Источник Nasdaq GlobeNewswire

Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders

17 июн 2024 15:45:00 Источник Nasdaq GlobeNewswire

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

10 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru to Present at the Jefferies Global Healthcare Conference

22 май 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

15 май 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

14 май 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

08 май 2024 05:30:00 Источник Nasdaq GlobeNewswire

Veru to Present at the GLP-1 Based Therapeutics Summit

02 май 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

01 май 2024 07:30:37 Источник Nasdaq GlobeNewswire

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

30 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

25 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru Announces Date of 2024 Annual Meeting of Shareholders

01 апр 2024 15:05:00 Источник Nasdaq GlobeNewswire

Veru Reschedules Annual Meeting of Shareholders

22 мар 2024 15:05:00 Источник Nasdaq GlobeNewswire

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

12 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

27 фев 2024 18:15:00 Источник Nasdaq GlobeNewswire

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

20 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru Reports Fiscal 2024 First Quarter Financial Highlights

08 фев 2024 05:30:00 Источник Nasdaq GlobeNewswire

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

06 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

31 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

25 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire